 "DOLO-650 makers distributed freebies worth Rs 1,000 cr to doctors: FMRAI")
The Central Board for Direct Taxes (CBDT) has accused the makers of the Dolo-650 tablet of spending Rs 1,000 crore to distribute freebies to doctors for prescribing the medicine.
In the Federation of Medical & Sales Representatives Association of India (FMRAI) vs Union of India case, advocate Sanjay Parikh, representing FMRAI, said that DOLO had invested the amount in 'freebies' to have it prescribed, according to Bar and Bench (B&B).
Public interest litigation (PIL) was filed in the court through advocate Aparna Bhat that sought statutory backing from the Uniform Code of Pharmaceutical Marketing Practices (UCPMP). It stated that the right to health is a part of the right to life, and pharma companies should adhere to ethical marketing practices.
Justice DY Chandrachud, heading the bench, said it is a serious issue. "This is not music to my ears. I was also asked to have the same when I had Covid. This is a serious issue and matter," he said, as quoted by B&B.
Also Read: Freebies, welfare schemes must be differentiated, says Supreme Court
Also Read: Freebies, welfare schemes must be differentiated, says Supreme Court
The central government has been directed to file a reply within ten days. It was being represented by additional solicitor general KM Natraj.
The petitioner further said that corruption in pharma marketing practices is unregulated in India. This is despite the country being a signatory to the UN Convention against corruption, the report added.
Currently, no law in India proscribes any such practice.
The plea added that such drugs threaten the patient's life and health. It also said that in this situation, the customer pays for branded medicines that are "over-prescribed" or "irrationally prescribed" by doctors.
It argued that giving a statutory basis to UCPMP will provide transparency and accountability in the process.
The government, however, released a draft UCPMP and invited comments from the public shortly after the hearing.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →Subscribe to Business Standard digital and get complimentary access to The New York Times
Quarterly Starter
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
Save 46%
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%